Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

GNPX vs AAPG: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

GNPX Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 5–5 Matrix Metrics)

GNPX Overall Winner 6-Pillar Tally: GNPX 2 – 2 AAPG (2 Tie) Matrix Metrics: GNPX 5 – 5 AAPG

As of Nov 20, 2026, Genprex, Inc. (GNPX) is the stronger overall head-to-head candidate over Ascentage Pharma Group International American Depository Shares (AAPG) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow). GNPX carries a Unified Composite Score of 42.2/100 (HOLD) at $1.45 (N/M Forward P/E, 0.0% operating margin), whereas AAPG carries 37.1/100 (SELL) at $11.97 (8.4x Forward P/E, -219.5% operating margin).

  • Growth vs. Quality Trade-Off: GNPX earns the overall head-to-head edge with a stronger Unified Composite Score (42.2/100 HOLD vs. AAPG 37.1/100 SELL) and -4.68β · 96% Vol risk profile, whereas AAPG leads top-line expansion (+29.3% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: GNPX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.6); meanwhile AAPG is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About GNPX vs AAPG
GNPX NASDAQ Head-to-Head Winner
Genprex, Inc. Common Stock
Pharmaceutical Preparations
$1.45
-13.17% 1D
Market Cap $2.2M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -4.68β · 96% Vol
Unified Composite Score
42.2 / 100 HOLD
Tech 25.0 Fund 47.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -22.2%), weak momentum, RSI 27
RSI-14: 26.6 · SMA20: $2.00 · SMA50: $2.48
AAPG NASDAQ
Ascentage Pharma Group International American Depository Shares
Pharmaceutical Preparations
$11.97
-3.78% 1D
Market Cap $1.2B
TTM Revenue $643M
Forward P/E 8.4x
Beta / 30D Vol 1.36β · 64% Vol
Unified Composite Score
37.1 / 100 SELL
Tech 25.0 Fund 42.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -7.6%), weak momentum, RSI 29
RSI-14: 28.8 · SMA20: $14.33 · SMA50: $14.97

6-Pillar Scorecard Institutional Category Breakdown (GNPX 2 – 2 AAPG)

Columns: Metric · GNPX · AAPG
1. Valuation Multiples AAPG
Forward P/E N/M 8.4x
Trailing P/E N/M 8.4x
PEG Ratio N/M N/M
EV / Revenue N/M 1.8x
2. Growth & Scale AAPG
Revenue Growth (YoY) +0.0% +29.3%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $643M
Market Cap $2.2M $1.2B
3. Profitability & Quality GNPX
Gross Margin N/A 93.9%
Operating Margin 0.0% -219.5%
Net Profit Margin 0.0% -228.5%
Return on Equity (ROE) -233.7% -236.6%
4. Balance Sheet & Cash Flow GNPX
Cash Generation (TTM) N/A -$1.34B EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $11.26 Book/Sh · -233.7% ROE $0.89 Book/Sh · -236.6% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: GNPX (5) vs AAPG (5)
Institutional Metric GNPX AAPG Criterion Row Edge
Market Capitalization
Scale
$2.2M $1.2B Larger Scale AAPG
Trailing P/E Ratio
Valuation
N/M 8.4x Lower Multiple AAPG
Forward P/E Ratio
Valuation
N/M 8.4x Lower Multiple AAPG
Revenue Growth (YoY)
Growth
+0.0% +29.3% Higher Growth AAPG
Operating Margin (TTM)
Profitability
0.0% -219.5% Higher Margin GNPX
Net Profit Margin
Profitability
0.0% -228.5% Higher Margin GNPX
Return on Equity (ROE)
Capital Efficiency
-233.7% -236.6% Higher ROE GNPX
52-Week Range Position
Momentum
11% ($0–$10) 0% ($12–$34) Stronger Trend GNPX
Beta / 30D Volatility
Risk Regime
-4.68β · 96% Vol 1.36β · 64% Vol Lower Realized Risk AAPG
Unified Institutional Score
Composite Signal
42.2 / 100 (HOLD) 37.1 / 100 (SELL) Higher Composite GNPX
Trailing 12M Revenue (USD)
Operating Scale
N/A $643M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 93.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 1.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($11.26 Book/Sh · -233.7% ROE) -$1.34B EBITDA ($0.89 Book/Sh · -236.6% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AAPG +7.0 pp
GNPX: -26.77% · AAPG: -19.77%
3M Horizon AAPG +35.56 pp
GNPX: -63.93% · AAPG: -28.37%
6M Horizon GNPX +123.05 pp
GNPX: +83.57% · AAPG: -39.48%
1Y Horizon GNPX +6.24 pp
GNPX: -56.59% · AAPG: -62.83%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on GNPX vs AAPG. Trailing 12-month operating profitability (GNPX 0.0% vs AAPG -219.5%) and valuation multiples (GNPX N/M vs AAPG 8.4x Forward P/E) are benchmarked directly in Pillar 4 below.

GNPX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-233.7% · N/M
AAPG ADR TTM Benchmark FX-Normalized USD
TTM Revenue$643M
Gross Margin93.9%
Op. Margin-219.5%
ROE / Fwd P/E-236.6% · 8.4x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
GNPX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact GNPX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AAPG UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew Thin ADR Chain
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AAPG Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
GNPX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
AAPG Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.2B market capitalization and -219.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ GNPX vs AAPG Key Questions & Quantitative Answers

As of Nov 20, 2026, Genprex, Inc. (GNPX) is the stronger overall head-to-head candidate over Ascentage Pharma Group International American Depository Shares (AAPG) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow). GNPX carries a Unified Composite Score of 42.2/100 (HOLD) at $1.45 (N/M Forward P/E, 0.0% operating margin), whereas AAPG carries 37.1/100 (SELL) at $11.97 (8.4x Forward P/E, -219.5% operating margin). Growth vs. Quality Trade-Off: GNPX earns the overall head-to-head edge with a stronger Unified Composite Score (42.2/100 HOLD vs. AAPG 37.1/100 SELL) and -4.68β · 96% Vol risk profile, whereas AAPG leads top-line expansion (+29.3% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: GNPX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.6); meanwhile AAPG is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 28.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AAPG leads the Growth & Scale pillar: GNPX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with AAPG at +29.3% YoY revenue growth and +0.0% YoY earnings growth on $643M TTM revenue (93.9% gross margin, -219.5% operating margin). On trailing 12-month operating scale, GNPX generates N/A in USD-normalized revenue versus $643M for AAPG. In operating R&D and SG&A reinvestment, GNPX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AAPG.

AAPG screens cheaper on headline valuation multiples. GNPX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas AAPG trades at 8.4x Forward P/E, 8.4x Trailing P/E, N/M PEG, and 1.8x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against GNPX (-233.7% ROE) versus AAPG (-236.6% ROE) capital efficiency.

In options market volatility and institutional positioning, GNPX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-4.68β · 96% Vol realized risk). By comparison, AAPG carries N/A implied volatility (N/A, Unclassified), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.36β · 64% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.